**Introduction**

Faecal immunochromatographic tests (FIT) are acceptable to a large part of the general population but used alone are poor at detecting adenomas. An ELISA which measures faecal M2-pyruvate kinase (M2-PK) has been shown to be useful for detecting colonic pathology.

**Aims** To prospectively compare M2-PK and FIT in screening for colonic polyps and cancer in the second round of our pilot FIT-based colorectal cancer screening programme.

**Methods** The second round of our FIT pilot programme was conducted over a two year period. Patients were sent invitations by post to return a FIT sample from each of two days. All participants were aged 50 – 74 and living locally to our hospital. As part of this round, over a six month period all invitations additionally included containers to collect a single M2-PK stool sample. All FIT’s returned on time were measured locally. All M2-PK samples received within 48 hours of passing stool were frozen and analysed centrally by ScheBo Biotech AG (Germany).

All FIT positive (>100ngHb/ml) or M2-PK positive (>4U/ml) patients were contacted and assessed for colonoscopy. All colonoscopies were conducted in the same way between both groups.

**Results** Over the six month period 1,800 combined M2-PK and FIT invites have been sent. 879 samples were returned and analysed for faecal M2-PK and FIT; of these 245 were positive for either one or both of these markers. After being contacted 34 (15%) of this group were excluded as they had a colonoscopy within 3 years and were all in polyp surveillance programmes.

Of the remaining patients: 30 (3.4% of 879) were FIT positive M2-PK negative; 160 (18.2%) were positive for M2-PK (> 4U/ml) negative for FIT and 21 (2.3%) were positive for both markers.

In the FIT positive M2-PK negative group there were 10 patients with adenomas (adenoma detection rate 33%). In those who were M2-PK positive but FIT negative there were 34 people with adenomas (ADR 23%). Therefore these adenomas would not have been detected by relying on FIT alone. Of the remaining 21 positive for both, 6 (29%) had adenomas and another 4 (19%) had colitis/proctitis. There have not been any cancers in this group to date.

Interestingly sessile serrated adenomas were detected in 5 (4.4%) of people M2-PK positive but only two (less than 1%) in our entire FIT positive group.

**Conclusion** Studies have shown FIT has relatively low sensitivity for adenomas. The addition of another stool marker such as faecal M2-PK increases the detection of polyps in a screening population. The addition of another stool marker such as faecal M2-PK sample detects more adenomas than two day FIT but further studies are needed to confirm this.

**Disclosure of Interest** None Declared
**OC-074** | THE ROLE OF THE FUNGAL MICROBIOTA IN THE PATHOGENESIS OF DE-NOVO PAEDIATRIC INFLAMMATORY BOWEL DISEASE USING NEXT GENERATION SEQUENCING

doi:10.1136/gutjnl-2013-304907.073

1R Hansen, 1Mukhopadhyya, 2C Meharg, 3R Russell, 4S Berry, 5E El-Omar, 6G Hold.
1Division of Applied Medicine, Aberdeen University; Aberdeen; 2Queens University Belfast; Belfast; 3Paediatric Gastroenterology, Royal Hospital for Sick Children, Glasgow, UK

**Introduction** Paediatric Inflammatory bowel disease (IBD) incidence is rising worldwide. Recently the role of the gut microbiota has been recognised as pivotal in disease pathogenesis. IBD microbiota studies to date have focused on bacterial diversity assessment in established disease cohorts, with limited studies in treatment naive patients. In contrast to bacteria, the exact role of the colonising fungi and their pathogenic potential has not been fully explored. The aim of the study was to examine candidate fungal triggers at disease onset in children with IBD using pyrosequencing, utilising the Bacteria in Inflammatory bowel disease in Scottish Children Undergoing Investigation before Treatment (BISCUIT) study cohort.

**Methods** 128 children undergoing colonoscopy were approached from three Scottish paediatric centres (Aberdeen, Glasgow and Dundee) with 100 ultimately recruited and biopsied; 44 IBD (comprising Crohn’s disease (CD); 29, ulcerative colitis (UC); 13) and IBD-type unspecified (2)), 42 normal colon controls (NCC) and 14 “others”. All IBD patient samples were taken from inflamed tissue. Fungal DNA was amplified on a reduced cohort of 37 recruits (13 CD, 12 UC, 12 NCC) using 185 rDNA primers. Roche 454 Titanium sequencing was conducted by NewGene (Newcastle, UK). Data analysis was performed using QIIME version 1.3.0 workflow. Taxonomy assignment of operational taxonomic units (OTUs) was performed according to ribosomal database project taxonomy. OTU tables were rarefied at 3,000 reads.

**Results** Fungal DNA was amplifiable from 7 patient samples, 6 children with a diagnosis of IBD – 4 with CD (BISCUIT31, 32, 62 and 89), 2 children with UC (BISCUIT33 and 104) and 1 NCC (BISCUIT 27). Fungal diversity was assessed in all paediatric samples alongside three adult samples to act as comparison. The adult samples comprised 1 patient with UC (2UC21Aa) and 2 NCC (GH4 and GH9). Phylum level analysis indicated that all fungal sequences belonged to the Ascomycota and Basidiomycota phyla. Control patients contained predominantly Ascomycota sequences (> 80% of sequences in all patients) whilst 6/7 IBD patients contained exclusively Basidiomycota species. Genus level analysis was undertaken and there was no similarity between fungal profiles from the paediatric and adult samples.

**Conclusion** By using robust methodology we have characterised the IBD “fungal microbiota” at diagnosis in children. Based on the current study, it would appear that a distinctly altered fungal species profile is present at IBD disease presentation. Further work should now focus on expanding this study and identifying how to beneficially modify the microbiota using established and novel IBD treatments.

**Disclosure of Interest** None Declared

---

**Endoscopy symposium: how I do it - ERCP**

**OC-075** | ANALYSIS OF LONG-TERM OUTCOMES AFTER ENDOSCOPIC RADIOFREQUENCY ABLATION FOR BILE DUCT STRUCTURES IN Pancreatic Malignancy SUGGESTS POTENTIAL SURVIVAL BENEFIT

doi:10.1136/gutjnl-2013-304907.074

1Y Kallis, 1N Phillips, 2A Steel, 3H Kaltsidis, 4J Nicholls, 5L Jiao, 6P Vilvianos, 7N Habib, 8D Westaby.
1Endoscopy, Royal London Hospital; Barts Health NHS Trust; 2HPB Unit, Imperial College Healthcare NHS Trust; 3Gastroenterology, Chelsea & Westminster NHS Foundation Trust, London, UK

**Introduction** Pancreatic carcinoma carries a poor prognosis with only 10–20% of patients amenable to attempts at curative surgery at presentation. Biliary obstruction is a common complication and many patients will require self-expanding metal stent (SEMS) insertion for definitive decompression. A recent pioneering phase I/II study in our tertiary referral centre demonstrated excellent safety and 90d stent patency with endobiliary radiofrequency ablation (RFA) as an adjunct to SEMS insertion. The longer-term impact of this novel endoscopic treatment modality on biliary drainage and patient survival in advanced pancreatic carcinoma is unknown.

**Objective** To investigate the longer-term efficacy of endobiliary RFA in the management of malignant bile duct obstruction associated with inoperable pancreatic carcinoma.

**Methods** Retrospective cohort analysis of 25 patients with resectable pancreatic carcinoma undergoing RFA + SEMS insertion, and 46 matched controls undergoing SEMS insertion alone, for malignant biliary obstruction in a single tertiary referral centre. Patients were stringently matched for age, sex, metastases, ASA/ co-morbidities, and intention to treat with palliative chemotherapy. Survival, maintenance of stent patency, and procedure-related complications were assessed.

**Results** RFA and control groups were closely matched- age 68.9 +/- 9.0y vs. 69.8 +/- 9.9y, p = 0.791; ASA 2.35 +/- 0.65 vs. 2.54 +/- 0.50, p = 0.086; metastases at treatment 9/23 (39.1%) vs. 18/46 (39.1%), p = 0.800; chemotherapy 16/23 (69.6%) vs. 24/46 (52.2%), p = 0.203. Median survival was 227d after RFA vs. 123.5d in controls (HR. 0.633 CI 0.378–1.060, p = 0.011). RFA was independently predictive of survival at 90d (OR 16.14, CI 1.35–193.18, p = 0.028) and 180d (OR 4.25, CI 1.00–18.01, p = 0.049). Overall SEMS patency rates were the same across both groups, though more patients were alive with a patent index SEMS after RFA within the first few months (73.9% vs. 41.3% at 4.5m, p = 0.012). Complications of RFA were few (1 pancreatitis, 1 cholangitis), with a median post-procedure inpatient stay of 1d (1–8).

**Conclusion** In the single largest case series to date, endobiliary RFA was found to be a safe and efficacious adjunctive treatment in the management of patients with advanced pancreatic malignancy and biliary obstruction, and demonstrated potential early survival benefit. These data suggest that endobiliary RFA could be an additional treatment option in advanced pancreatic carcinoma, and form the basis from which future prospective clinical trials of this novel treatment modality can be designed.


**OC-076** | SYRINGE SIZE INFLUENCES THE AMOUNT OF MIDAZOLAM ADMINISTERED DURING SEATED ENDOSCOPY

doi:10.1136/gutjnl-2013-304907.075

1D Haldar, 2N Quraishi, 1K Glover, 1S Keen, 1A D Farmer.
1Gastroenterology, South Shropshire CCG; 2HPB Unit, Imperial College Healthcare NHS Trust; 3Gastroenterology, Chelsea & Westminster NHS Foundation Trust, London, UK

**Introduction** By using robust methodology we have characterised the IBD “fungal microbiota” at diagnosis in children. Based on the current study, it would appear that a distinctly altered fungal species profile is present at IBD disease presentation. Further work should now focus on expanding this study and identifying how to beneficially modify the microbiota using established and novel IBD treatments.

**Disclosure of Interest** None Declared
OC-073 Risks of Major Congenital Anomalies in Children Born to Women with Inflammatory Bowel Disease: a United Kingdom Population-Based Cohort Study
L Ban, L J Tata and T Card

Gut 2013 62: A31-A32
doi: 10.1136/gutjnl-2013-304907.072

Updated information and services can be found at:
http://gut.bmj.com/content/62/Suppl_1/A31.2

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Ulcerative colitis (1113)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/